Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daclizumab in RRMS switching from Natalizumab
NCT02881567Phase 3Terminated
- Sponsor
- Biogen
- Start
- Apr 2017
- Primary completion
- Sep 2018
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 3 trial of daclizumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Biogen. Started Apr 2017; status: terminated.
02
Drugs
daclizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT02881567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02881567.